Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 541 - 550 of 763 studies

Cancer and neoplasms

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-16673-304)

Cancer and neoplasms Metabolic and Endocrine

A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMORS (XL092-311 (STELLAR-311))

Neurological

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Intravenous Prasinezumab In Participants With Early Parkinson’s Disease (BN44715 (PARAISO))

Respiratory

A Phase 2b/3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig compared with placebo in adult participants with moderate-to-severe chronic obstructive pulmonary disease with type 2 inflammation.. (PERSEPHONE)

United Kingdom Register of Stored Ovarian and Testicular Tissue (UKSTORE)

A Non-interventional, Epidemiologic Study of XLMTM and Clinical Expression in the Liver

Real-World Effectiveness of Belumosudil for the Treatment of Chronic Graft vs. Host Disease: A Non-interventional Retrospective Cohort Study Using Patient Medical Records (ROCKreal2)

Cancer and neoplasms

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON−SMALL CELL LUNG CANCER (KRASCENDO-2)

NeoRet: Creating a Retinal Growth Chart for Early Life (NeoRet)

Inflammatory and immune system

A randomized, double-blind, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease (EFC17359 (RILIEF))